Entéropathie induite par les sartans [Sartan-induced enteropathy]
Details
Request a copy Under embargo until 18/03/2026.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_0D7D80A58C4F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Entéropathie induite par les sartans [Sartan-induced enteropathy]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
18/09/2024
Peer-reviewed
Oui
Volume
20
Number
887
Pages
1665-1668
Language
french
Notes
Publication types: Journal Article ; Case Reports ; English Abstract
Publication Status: ppublish
Publication Status: ppublish
Abstract
Olmesartan-induced enteropathy was first described twelve years ago. Clinically it is characterized by diarrhea, weight loss and malabsorption. Histological analysis may show duodenal villous atrophy and/or epithelial lymphocytosis (duodenal/colic). Celiac-specific antibodies are negative and gluten avoidance does not improve the symptomatology. This adverse event can occur months or years after the introduction of the causative drug, making it a real diagnostic challenge. The treatment is the avoidance of olmesartan, which will lead to both clinical and histological improvement.
Keywords
Humans, Imidazoles/adverse effects, Imidazoles/administration & dosage, Tetrazoles/adverse effects, Angiotensin II Type 1 Receptor Blockers/adverse effects, Intestinal Diseases/chemically induced, Intestinal Diseases/diagnosis, Diarrhea/chemically induced, Weight Loss
Pubmed
Create date
25/09/2024 8:30
Last modification date
26/09/2024 6:20